Targeting a specific gene could be key to treating hepatitis B, C and D
“Chronic viral hepatitis is the long-term inflammation of the liver. It is caused by hepatitis B, C or D virus particles. Even though these viruses replicate differently, they all use the endoplasmic reticulum-Golgi pathway for replication, where the TM5SF2 gene is located.”
Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis
“The high rates of the sustained virologic response 12 weeks after treatment (SVR12) in real world settings provoked the adoption of shortened courses of the costly direct-acting antivirals (DAAs) regimens. This study provides, to our knowledge, the first systematic review and meta-analysis for the efficacy of the shortened 8-week course of sofosbuvir (SOF) plus daclatasvir (DCV), the most accessible DAAs in the low-middle income countries (LMICs).”
35 Health Advocacy Groups Urge the Supreme Court to Protect Preventive Care
“[On October 21] 35 organizations, representing millions of patients with serious health conditions and thousands of health care professionals, filed an amicus curiae, or “friend-of-the-court,” brief in the case of Braidwood v. Becerra at the U.S. Supreme Court. The amicus brief supports the government’s petition for certiorari in the case, providing extensive scientific data demonstrating that preventive services save lives and are cost-effective. At the crux of the case is a provision of the Affordable Care Act (ACA) that requires most insurers cover preventive services recommended by the United States Preventive Services Task Force (USPSTF) without cost-sharing by patients.”
Minicircle-based vaccine induces potent T-cell and antibody responses against hepatitis C virus
“An effective vaccine against hepatitis C virus (HCV) should elicit both humoral and cellular immune responses.”
Use of Hepatitis C Viremic Donors to Expand the Pediatric Donor Pool
“The use of hepatitis C virus (HCV)-positive donors in organ transplantation has become increasingly viable due to advancements in direct-acting antiviral (DAA) therapies, which offer high cure rates. This review aims to evaluate the current practices, benefits, and challenges of utilizing HCV-positive donors for organ transplantation.”
